Skip to content
approvedWeight Loss & Diabetes

Exenatide Extended-Release

Also known as: Bydureon, Bydureon BCise, Exenatide ER, Exenatide LAR, Exenatide Once-Weekly

Exenatide extended-release (Bydureon) is a once-weekly injectable GLP-1 receptor agonist that encapsulates the Gila monster venom-derived peptide exenatide in biodegradable poly(D,L-lactide-co-glycolide) microspheres. FDA-approved in 2012, it provides continuous GLP-1 receptor activation from a single weekly injection, reducing HbA1c by approximately 1.3–1.6% with improved gastrointestinal tolerability compared to the twice-daily formulation (Byetta). The EXSCEL cardiovascular outcomes trial confirmed cardiovascular safety.

3 cited references·6 researched benefits

Quick Answer

Exenatide extended-release (Bydureon) is a once-weekly injectable GLP-1 receptor agonist for type 2 diabetes that uses microsphere technology to slowly release exenatide, the Gila monster venom-derived peptide, over seven days. FDA-approved in 2012, it reduces HbA1c by 1.3–1.6% and promotes modest weight loss of 2–4 kg. It has better gastrointestinal tolerability than twice-daily Byetta due to more stable drug levels, though injection-site nodules are more common.

Key Facts

Mechanism
Exenatide extended-release uses poly(D,L-lactide-co-glycolide) (PLG) microspheres that slowly degrade after subcutaneous injection, releasing exenatide continuously over approximately 7 days. The released exenatide activates GLP-1 receptors on pancreatic beta cells, increasing cAMP-mediated glucose-dependent insulin secretion. It simultaneously suppresses glucagon from alpha cells, slows gastric emptying, and acts on hypothalamic satiety centers to reduce appetite. The steady-state pharmacokinetics achieved after 6–7 weeks of weekly dosing provide more consistent GLP-1 receptor activation compared to the peak-trough pattern of twice-daily Byetta, resulting in slightly better HbA1c reduction with less nausea.
Research Status
approved
Half-Life
~2 weeks (microsphere depot release; peptide half-life ~2.4 hours)
Molecular Formula
C₁₈₄H₂₈₂N₅₀O₆₀S (exenatide peptide)
Primary Use
Weight Loss & Diabetes
Table of Contents

Benefits

  • Convenient once-weekly dosing improves adherence compared to twice-daily Byettastrong
  • HbA1c reduction of 1.3–1.6% in clinical trials (DURATION program)strong
  • Weight loss of 2–4 kg without dietary requirement — sustained over long-term treatmentstrong
  • Cardiovascular safety confirmed by EXSCEL trial (14,752 patients, median 3.2-year follow-up)strong
  • Lower nausea incidence compared to immediate-release exenatide due to stable plasma levelsmoderate
  • Potential neuroprotective effects — GLP-1 receptor activation in brain linked to Parkinson disease benefitpreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Subcutaneous injection2 mgOnce weeklyFixed dose. Inject on the same day each week, any time of day, with or without meals. Rotate injection sites among abdomen, thigh, and upper arm. Allow vial to reach room temperature for 15 minutes before reconstitution. Bydureon BCise autoinjector requires no reconstitution.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Injection-site nodules — palpable subcutaneous lumps at injection site due to microsphere depot, resolving over 4–8 weekscommon
  • Nausea — affects 10–20% of patients (less than twice-daily formulation)common
  • Diarrhea, vomiting, and constipation — gastrointestinal effects in 5–10% of patientscommon
  • Injection-site pruritus and erythemacommon
  • Acute pancreatitis — rare but serious; discontinue if persistent severe abdominal pain occursserious
  • Acute kidney injury — rare, primarily in patients with pre-existing renal impairment or severe dehydrationserious

Frequently Asked Questions

What is the difference between exenatide ER (Bydureon) and immediate-release exenatide (Byetta)?
Both contain the same exenatide peptide, but the delivery systems differ. Byetta is injected twice daily before meals, producing peak-trough drug levels. Bydureon uses biodegradable microspheres that slowly release exenatide over a week, requiring only one weekly injection. Bydureon achieves slightly better HbA1c reduction (1.6% vs 1.3%) with significantly less nausea (11% vs 35%), though injection-site nodules are unique to the extended-release formulation. Bydureon BCise further simplifies administration with a single-dose autoinjector requiring no reconstitution.
How long does it take for Bydureon to reach full effectiveness?
Bydureon requires approximately 6–7 weeks of weekly dosing to reach steady-state plasma concentrations. During this ramp-up period, patients may notice gradual improvements in blood glucose control, but full efficacy is not achieved until steady state. This is because the microspheres from each injection continue releasing exenatide over several weeks, and overlapping releases from consecutive injections build to therapeutic levels. Patients should not judge effectiveness until at least 8–10 weeks of consistent use.
Can exenatide ER be used for weight loss in non-diabetic patients?
Exenatide ER is FDA-approved only for type 2 diabetes, not for weight loss as a standalone indication. While it does produce modest weight loss (2–4 kg), this is significantly less than newer GLP-1 RAs like semaglutide (Wegovy), which produces 15–17% body weight loss. Off-label use for weight loss exists but is not supported by the same level of evidence as semaglutide. For dedicated weight management, semaglutide or tirzepatide are more effective options.
Why are there lumps at the injection site with Bydureon?
The subcutaneous nodules are caused by the PLG (poly-lactide-co-glycolide) microspheres that encapsulate exenatide. After injection, these biodegradable polymer particles form a small depot under the skin that gradually dissolves over 4–8 weeks as it releases the drug. The nodules are not harmful and typically resolve on their own. Rotating injection sites helps minimize their visibility and any associated discomfort.

References

  1. 1
    Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4)(2012)PubMed ↗
  2. 2
    Once-weekly exenatide and cardiovascular outcomes in type 2 diabetes: a systematic review and meta-analysis(2014)PubMed ↗
  3. 3
    Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL)(2017)PubMed ↗

Latest Research

Last updated: 2026-02-19